Novo Nordisk's Wegovy and Semaglutide Reduce Heart Failure and COVID-19 Mortality

Aug 30, 2024, 09:14 AM

Novo Nordisk's weight loss drug Wegovy, which contains semaglutide, has shown promising results in reducing the risk of severe complications in patients with heart failure and obesity. A new analysis reveals that Wegovy cuts the chances of patients dying from COVID-19 by roughly a third compared to a placebo. Additionally, semaglutide has been found to reduce the risk of heart failure events and cardiovascular death by up to 29%. A study involving 3,533 diabetic patients reported a 27% lower risk of heart-related issues. The benefits of semaglutide extend beyond symptoms and functional capacity, reducing emergency hospitalization visits and a composite endpoint including cardiovascular death. Furthermore, a Harvard study indicates that Ozempic and Wegovy lower the risk of severe COVID-19 in people with obesity. The SELECT trial also demonstrated reduced COVID-19 associated morbidity and mortality. In a large randomized trial, there was a significant reduction of all-cause mortality.